Karlyne M. Reilly, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- 37 Convent Drive, Room 1056
- Bethesda, MD 20814
- 240-760-7115
- reillyk@mail.nih.gov
RESEARCH SUMMARY
Dr. Reilly received her Ph.D. in molecular and cellular biology from Harvard University and trained as a post-doctoral fellow at the Center for Cancer Research of MIT, where she held fellowships from the Leukemia & Lymphoma Society, the AACR-Sidney Kimmel Foundation, and the American Cancer Society. She came to the CCR in 2002 and established the Genetic Modifiers of Tumorigenesis Group. In 2016, she was appointed director of the Rare Tumors Initiative. Her research focuses on mechanisms of susceptibility to nervous system tumors and preclinical models of tumors associated with neurofibromatosis type 1 (NF1).
Areas of Expertise
Research
Developing New Preclinical Models and Testing Candidate Therapies for MPNST
Malignant peripheral nerve sheath tumors (MPNST) are one of the deadliest sarcomas and are at an increased incidence in neurofibromatosis type 1 (NF1). In the setting of NF1, MPNSTs arise through transformation of an existing benign plexiform neurofibroma (PNF), making early detection of the cancer challenging. We are working to better model and understand the biology underlying MPNST using mouse models and mouse and human MPNST cell lines and are testing candidate therapeutics for treatment of MPNST.
The Rare Tumor Initiative
Rare tumors are defined as affecting less than 40,000 new patients each year, or less than 200,000 patients overall in the U.S. Although individual tumor types are rare, taken together rare tumors account for 27% of all cancers diagnosed and lead to 25% of cancer-related deaths. All pediatric tumors, nervous system tumors, and sarcomas are rare. Research on rare tumors is difficult due to the low number of patients affected, and thus many rare tumors lack effective treatment options. The Rare Tumor Initiative (RTI) is working to reduce barriers and address the challenges of CCR investigators studying rare tumors and developing new therapies. The RTI is particularly focused on improving opportunities for basic-clinical collaborations to promote the “bench-to-bedside-and-back” paradigm of cancer research.
My Pediatric and Adult Rare Tumor Network
Due to the paucity of data on rare tumors, it is difficult to develop targeted treatments. We are using biospecimens collected on a natural history study of rare solid tumors established by the My Pediatric and Adult Rare Tumor network (MyPART), RTI, to identify new targets for treatment. We are focusing on tumors that affect children, adolescents, and young adults, using next-generation sequencing, tumor cell models, and mouse models to develop candidate therapeutics, with a particular focus on poorly differentiated chordoma and other SMARCB1-deficient rare tumors.
Publications
- Bibliography Link
- View Dr. Reilly's Complete Bibliography at NCBI.
The Rare Tumor Initiative in the National Cancer Institute: Harnessing expertise and existing resources to develop therapies for rare tumors
Developing therapies for rare tumors: opportunities, challenges and progress
M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma
Deguelins, Natural Product Modulators of NF1-Defective Astrocytoma Cell Growth Identified by High-Throughput Screening of Partially Purified Natural Product Extracts
Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
Biography
Karlyne M. Reilly, Ph.D.
Dr. Reilly received her Ph.D. in molecular and cellular biology from Harvard University under Dr. Douglas Melton studying mesoderm induction and axis formation in Xenopus laevis. She trained as a post-doctoral fellow at the Center for Cancer Research of MIT, under Dr. Tyler Jacks, where she held fellowships from the Leukemia & Lymphoma Society, the AACR-Sidney Kimmel Foundation, and the American Cancer Society. As a post-doctoral fellow, she studied genetic modifiers of cancers associated with neurofibromatosis type 1 and characterized the first mouse model of astrocytoma and glioblastoma generated through tumor suppressor mutation. She came to the CCR in 2002 and established the Genetic Modifiers of Tumorigenesis Group where she continued her work on modifiers of nervous system tumorigenesis, identifying genetic loci affecting astrocytoma/glioblastoma, spinal astrocytoma, and malignant peripheral nerve sheath tumors. In 2016, she was appointed director of the Rare Tumor Initiative. Her current research focuses on mechanisms of susceptibility to nervous system tumors and preclinical models of tumors associated with neurofibromatosis type 1 (NF1).
